Radiopharmaceuticals

Sep 22, 2026

Novo’s CagriSema Demonstrates Superior Weight Loss Over Tirzepatide in REIMAGINE 5 Novo Nordisk announced topline results from the Phase 3 REIMAGINE 5 and REDEFINE 9 trials evaluating once-weekly CagriSema (cagrilintide and semaglutide), an investigational therapy and the company’s next-generation approach to we...

Apr 14, 2026

IDEAYA Biosciences and Servier Advance Darovasertib Program with Positive Registrational Trial Results IDEAYA Biosciences and Servier have announced positive topline findings from the Phase 2/3 OptimUM-02 registrational trial evaluating the combination of darovasertib and crizotinib. The study targeted patients ...

Apr 01, 2026

Radiopharmaceuticals are a cornerstone of precision medicine, enabling clinicians to visualize disease at the molecular level while simultaneously delivering targeted radionuclide therapy to tumors and other pathological tissues. Their dual diagnostic and therapeutic potential has positioned them as a transformativ...

Dec 05, 2025

Glypican-3 (GPC3) has emerged as one of the most promising therapeutic targets in oncology, particularly in hepatocellular carcinoma and select solid tumors. As a cell surface heparan sulfate proteoglycan that is overexpressed in approximately 75% of hepatocellular carcinoma cases while remaining virtually absent i...

Dec 21, 2022

Nuclear Medicine is an integral part of today’s healthcare delivery system and provides an immense benefit to patient care. Over the past four-five decades, there has been intense growth in the Nuclear Medicine Market owing to the development of various radionuclide and radio-labeled compounds and equipment. The ap...